The effectiveness of financial incentives for COVID-19 vaccination: A systematic review

Preventive Medicine, Journal Year: 2023, Volume and Issue: 172, P. 107538 - 107538

Published: May 6, 2023

Language: Английский

---

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era

Expert Review of Vaccines, Journal Year: 2023, Volume and Issue: 22(1), P. 650 - 661

Published: July 7, 2023

Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein. In response to the emergence sub-lineages, variant-adapted that contain encode for protein components have been developed.Areas covered This review presents currently available clinical immunogenicity safety data on versions BNT162b2 messenger RNA (mRNA) vaccine summarizes expected mechanism action, rationale development, these vaccines. addition, challenges encountered during development regulatory approval are discussed.Expert opinion Omicron-adapted provide a wider breadth potentially more durable protection against antigenically aligned variants when compared with original vaccine. As SARS-CoV-2 continues evolve, further updates may be required. To facilitate this, globally harmonized process transition updated is needed. Next-generation approaches broader future variants.

Language: Английский

---

Development of variant‐proof severe acute respiratory syndrome coronavirus 2, pan‐sarbecovirus, and pan‐β‐coronavirus vaccines

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 95(1)

Published: Sept. 26, 2022

Abstract The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants with high transmission rates and striking immune evasion have posed a serious challenge to the application of current first‐generation SARS‐CoV‐2 vaccines. Other sarbecoviruses, such as SARS‐CoV SARS‐related coronaviruses (SARSr‐CoVs), potential cause outbreaks in future. These facts call for development variant‐proof SARS‐CoV‐2, pan‐sarbecovirus or pan‐β‐CoV Several novel vaccine platforms been used develop vaccines broad‐spectrum neutralizing antibody responses protective immunity combat its variants, other well β‐CoVs, In this review, we discussed major target antigens efficacy summarized recent advances against sarbecoviruses β‐CoVs.

Language: Английский

---

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

Emerging Microbes & Infections, Journal Year: 2023, Volume and Issue: 12(2)

Published: Aug. 3, 2023

The threat to global health caused by three highly pathogenic human coronaviruses (HCoV), SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV therapeutics vaccines. This study reports design engineering a recombinant protein designated HR1LS. It contains linked molecules, each consisting structural domains, including heptad repeat 1 (HR1), central helix (CH), stem (SH) region, in S2 subunit SARS-CoV-2 spike (S) protein. was found that HR1LS automatically formed trimer able bind with 2 (HR2) region subunit, thus potently inhibiting HCoV fusion entry into host cells. Furthermore, immunization mice HR1LS, when combined CF501 adjuvant, resulted production neutralizing antibodies against infection its variants, as well MERS-CoV, HCoV-229E, HCoV-NL63 MjHKU4r-CoV-1. These results suggest is promising candidate further novel HR1-trimer-based inhibitor or vaccine treatment prevention but also other HCoVs potential cause future emerging re-emerging infectious coronavirus diseases.

Language: Английский

---

Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 498 - 509

Published: May 2, 2024

Background Vaccination remains the cornerstone of defense against COVID-19 globally. This study aims to assess safety and immunogenicity profile innovative vaccines LYB001.

Language: Английский

---

Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Abstract The development of a globally effective COVID‐19 vaccine faces significant challenges, particularly in redirecting the B‐cell response from immunodominant yet variable regions viral proteins toward their conserved domains. To address this, an integrated strategy is implemented that combines classical epitope prediction with protein‐antibody cluster docking and antibody titer analysis 30 vaccinated convalescent individuals. This approach yields stable immunoprevalent epitopes capable eliciting robust responses BALB/c mice effectively neutralizing pseudoviruses expressing Spike protein SARS‐CoV‐2 variants concern, including Alpha, Beta, Gamma, Delta, Omicron. achieve broader T‐cell‐based immune response, promiscuous T‐cell are identified by integrating predictions, differential scanning fluorimetry, peptide‐MHC structural analysis. Unique peptides MHC‐anchoring residues identified, enabling binding to spectrum MHC‐I MHC‐II haplotypes. These elicit strong interferon gamma human peripheral blood mononuclear cells demonstrate cross‐species efficacy activating both CD4+ CD8+ T‐cells mice. Collectively, these findings highlight significance innovative strategies targeting immunodominant/immunoprevalent drive broad humoral cellular against wide range variants.

Language: Английский

---

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: March 15, 2023

Language: Английский

---

The Immunogenicity of CpG, MF59-Like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice

Vaccines, Journal Year: 2024, Volume and Issue: 12(1), P. 60 - 60

Published: Jan. 7, 2024

The continuous evolution and mutation of SARS-CoV-2 have highlighted the need for more effective vaccines. In this study, CpG, MF59-like, Alum adjuvant Delta strain inactivated vaccines were prepared, immunogenicity these in mice was evaluated. + MF59-like vaccine group produced highest levels S- RBD-binding antibodies live virus neutralization after one shot immunization, while had two doses, groups high cross-neutralization against prototype, Beta, Gamma viruses. There no significant decrease neutralizing antibody any during observation period. excited different subtypes compared with unadjuvanted vaccines; CpG a higher proportion IgG2b antibodies, indicating bias towards Th1 immunity. proportions IgG1 similar to those vaccine. However, Th2 Antigen-specific cytokine secretion CD4/8+ T cells analyzed. conclusion, results study show differences immune efficacy mice, which implications selection strategy adjuvants.

Language: Английский

---

Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters

Vaccine, Journal Year: 2024, Volume and Issue: 42(4), P. 738 - 744

Published: Jan. 18, 2024

In the quest for heightened protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, we engineered a prototype vaccine utilizing plant expression system of Nicotiana benthamiana, to produce recombinant SARS-CoV-2 virus-like particle (VLP) presenting S-protein from Beta (B.1.351) variant concern (VOC). This innovative vaccine, formulated with either squalene oil-in-water emulsion or synthetic CpG oligodeoxynucleotide adjuvant, demonstrated efficacy in golden Syrian Hamster challenge model. The VLP induced robust humoral immune response, serum exhibiting neutralization not only but also cross-neutralizing Delta and Omicron pseudoviruses. Protective was demonstrated, evidenced by reduced viral RNA copies mitigated weight loss lung damage compared controls. compelling data instills confidence creation versatile platform local manufacturing potential pan-sarbecovirus vaccines, evolving threats.

Language: Английский

---

Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice

Viruses, Journal Year: 2023, Volume and Issue: 15(3), P. 687 - 687

Published: March 6, 2023

The emergence of new immune-evasive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and subvariants outpaces the development vaccines specific against dominant circulating strains. In terms only accepted immune correlate protection, inactivated whole-virion vaccine using wild-type SARS-CoV-2 spike induces a much lower serum neutralizing antibody titre Omicron subvariants. Since given intramuscularly is one most commonly used disease 2019 (COVID-19) in developing regions, we tested hypothesis that intranasal boosting after intramuscular priming would provide broader level protection. Here, showed or two boosts with Fc-linked trimeric receptor-binding domain from can induce significantly higher antibodies subvariants, including BA.5.2 XBB.1, bronchoalveolar lavage vaccinated Balb/c mice than vaccination four doses whole virion vaccine. intranasally K18-hACE2-transgenic also had nasal turbinate viral load, suggesting better protection upper airway, which predilected site infection by This approach achieves cross-protection may lengthen interval required for changing immunogen months to years.

Language: Английский

---